I am a
Home I AM A Search Login

Papers of the Week


Papers: 19 Dec 2020 - 25 Dec 2020


Human Studies, Pharmacology/Drug Development

PAIN TYPE:
Migraine/Headache


2020 Dec 15


Lancet

Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial.

Authors

Croop R, Lipton RB, Kudrow D, Stock DA, Kamen L, Conway CM, Stock EG, Coric V, Goadsby PJ
Lancet. 2020 Dec 15.
PMID: 33338437.

Abstract

Rimegepant is a calcitonin gene-related peptide receptor antagonist that has shown efficacy and safety in the acute treatment of migraine. We aimed to compare the efficacy of rimegepant with placebo for preventive treatment of migraine.